AI drug discovery may be finding its real scaling law. ๐งฌ
As Claude and other frontier models move deeper into biology, the bottleneck is shifting from model capability to proprietary biological data and real-world feedback.
That puts companies with unique data assets in focus. $TEM, for example, has built 500+ PB of molecular and clinical data across 45M+ de-identified patient journeys.
The next AI drug race may be less about who has the biggest model โ and more about who can build the fastest data โ prediction โ validation โ feedback loop.
Trade $TEM on StableStock:
โ
#
AIDrugDiscovery# #
Biotech# #
TEM#
Not investment advice. For informational purposes only.